Infectious complications of pentostatin therapy.

J. M. Vose, F. Cabanillas, S. O'Brien, N. Dang, R. Drapkin, F. Foss

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Managing the infectious complications associated with pentostatin (Nipent), used alone or in combination with other agents in patients with low-grade lymphomas, poses a significant problem for clinicians. Since there is limited experience with these therapies, definitive treatment recommendations concerning prophylaxis cannot be made. The panel members discussed the use of valacyclovir (Valtrex) to provide prophylaxis for herpes zoster, trimethoprim/sulfamethoxazole for Pneumocystis, and acyclovir (Zovirax) for varicella zoster. They also considered combinations of pentostatin with agents such as interferon, rituximab (Rituxan), and chlorambucil (Leukeran) and their effect on the immune system. The biology of B and T cells was discussed, with an emphasis on clinical application.

Original languageEnglish (US)
Pages (from-to)41-42
Number of pages2
JournalOncology (Williston Park, N.Y.)
Volume14
Issue number6 Suppl 2
StatePublished - Jun 2000

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Infectious complications of pentostatin therapy.'. Together they form a unique fingerprint.

  • Cite this

    Vose, J. M., Cabanillas, F., O'Brien, S., Dang, N., Drapkin, R., & Foss, F. (2000). Infectious complications of pentostatin therapy. Oncology (Williston Park, N.Y.), 14(6 Suppl 2), 41-42.